首页|复方木尼孜其颗粒联合枸地氯雷他定治疗湿疹的临床研究

复方木尼孜其颗粒联合枸地氯雷他定治疗湿疹的临床研究

扫码查看
目的 分析复方木尼孜其颗粒与枸地氯雷他定片联合治疗湿疹的临床效果。方法 选取 2021 年3 月—2023 年3月在苏州市第九人民医院就诊的 100 例湿疹患者为研究对象,按随机信封法将患者分为对照组和治疗组,各 50 例。对照组温水送服枸地氯雷他定片,1 片/次,1 次/d。治疗组在对照组基础上温水冲泡后送服复方木尼孜其颗粒,1 袋/次,3 次/d。两组连续服用 7 d。比较两组临床疗效、皮损情况、生活质量、免疫功能和炎症因子。结果 治疗后,治疗组患者的总有效率 86。00%高于对照组总有效率 68。00%(P<0。05)。治疗后,两组湿疹面积及严重指数(EASI)评分、瘙痒程度评分均显著下降(P<0。05),且治疗组EASI评分、瘙痒程度评分低于对照组(P<0。05)。治疗后,两组皮肤病生活质量量表(DLQI)评分均下降(P<0。05),且治疗组 DLQI 评分低于对照组(P<0。05)。治疗后,两组患者 CD3+、CD4+水平升高,CD8+水平下降(P<0。05);且治疗组CD3+、CD4+高于对照组,CD8+水平低于对照组(P<0。05)。治疗后,两组血清白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)水平下降,白细胞介素-10(IL-10)水平升高(P<0。05);且治疗组血清IL-6、TNF-α水平低于对照组,IL-10 水平高于对照组(P<0。05)。结论 复方木尼孜其颗粒联合枸地氯雷他定片可有效促进湿疹患者皮损恢复,改善生活质量,提高免疫功能,降低炎症反应。
Clinical study on Compound Muniziqi Granules combined with desloratadine in treatment of eczema
Objective To analyze the efficacy of the combination of Compound Muniziqi Granules and Desloratadine Citrate Disodium Tablets in treatment of eczema.Methods A study was conducted on 100 patients with eczema admitted to Suzhou Ninth People's Hospital from March 2021 to March 2023.They were divided into control group and treatment group using a random envelope method,with 50 patients in each group.Patients of the control group were po administered with Desloratadine Citrate Disodium Tablets,1 tablets/time,once daily.Patients of the treatment group were po administered with Compound Muniziqi Granules on the basis of the control group,1 bag/time,3 times daily.Patients in both groups were treated for 7 d.The total effective rate,skin lesions,quality of life,immune function,and inflammatory factors were compared between two groups.Results The total effective rate(86.00%)of the treatment group was higher than 68.00%of the control group(P<0.05).After treatment,EASI score and pruritus degree score decreased significantly(P<0.05),and EASI score and pruritus degree score in the treatment group were lower than those in the control group(P<0.05).After treatment,the levels of CD3+and CD4+in both groups increased,while the levels of CD8+in both groups decreased(P<0.05).The levels of CD3+and CD4+in treatment group were higher than those in the control group,but the levels of CD8+in treatment group was lower than that in the control group.After treatment,the serum levels of IL-6 and TNF-α in both groups were decreased,while the serum levels of IL-10 in both groups were increased(P<0.05).The serum levels of IL-6 and TNF-α in the treatment group were lower than those in the control group,while the serum levels of IL-10 in the treatment group were higher than those in the control group(P<0.05).Conclusion Compound Munizizi Granules combined with Desloratadine Citrate Disodium Tablets can effectively promote the recovery of skin lesions in eczema patients,improve the quality of life,enhance immune function and reduce inflammation.

Compound Muniziqi GranulesDesloratadine Citrate Disodium TabletseczemaEASI scoreitching degree scoreDLQI scoreCD3+CD4+CD8+IL-6TNF-αIL-10

孙一帆、闵玮、朱晓萍、王丹

展开 >

苏州市第九人民医院 皮肤科,江苏 苏州 215200

苏州大学附属第一医院 皮肤科,江苏 苏州 215200

复方木尼孜其颗粒 枸地氯雷他定片 湿疹 EASI评分 瘙痒程度评分 DLQI评分 CD3+ CD4+ CD8+ 白细胞介素-6 肿瘤坏死因子-α 白细胞介素-10

江苏省卫生健康委科研项目

H2019050

2024

现代药物与临床
天津药物研究院,中国药学会

现代药物与临床

CSTPCD
影响因子:1.179
ISSN:1674-5515
年,卷(期):2024.39(10)
  • 12